Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Inovio Pharmaceuticals, Inc.    INO

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
Delayed Quote. Delayed Nasdaq - 07/10 04:00:00 pm
23.38 USD   +0.47%
07/05Coronavirus Is No Cure for Health-Care Stocks
DJ
07/05Correction to Poor Performance of Health-Care Stocks Article
DJ
07/05Coronavirus Is No Cure for Health-Care Stocks
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the past twelve months, EPS forecast has been revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The tendency within the weekly time frame is positive above the technical support level at 8.32 USD
Weaknesses
  • The company has insufficient levels of profitability.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The group usually releases earnings worse than estimated.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
INOVIO PHARMACEUTICALS, INC..608.48%3 679
LONZA GROUP49.26%41 689
CELLTRION, INC.79.28%36 203
SEATTLE GENETICS, INC.52.59%31 361
IQVIA HOLDINGS INC.-7.66%27 688
MODERNA, INC.220.09%25 262
INCYTE CORPORATION23.53%23 448
ALNYLAM PHARMACEUTICALS, IN..40.88%18 345
GALAPAGOS NV-7.99%13 114
HANGZHOU TIGERMED CONSULTIN..68.35%11 188
PHARMARON BEIJING CO., LTD.99.94%10 994
BIO-TECHNE CORPORATION24.09%10 602
PPD, INC.0.00%10 193
QIAGEN N.V.31.80%10 179
IMMUNOMEDICS, INC.95.27%9 767
CHARLES RIVER LABORATORIES ..21.19%9 162
More Results
Financials (USD)
Sales 2020 13,6 M - -
Net income 2020 -111 M - -
Net Debt 2020 - - -
P/E ratio 2020 -33,4x
Yield 2020 -
Capitalization 3 696 M 3 696 M -
EV / Sales 2019
Capi. / Sales 2020 273x
Nbr of Employees 190
Free-Float 97,5%
Upcoming event on INOVIO PHARMACEUTICALS, IN
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes